Last update 26 Dec 2024

Entinostat

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Entinostat (JAN/USAN/INN), N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide, N-[[4-[(2-aminoanilino)-oxomethyl]phenyl]methyl]carbamic acid 3-pyridinylmethyl ester
+ [13]
Target
Mechanism
HDAC inhibitors(Histone deacetylase inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (EU)
Login to view timeline

Structure

Molecular FormulaC21H20N4O3
InChIKeyINVTYAOGFAGBOE-UHFFFAOYSA-N
CAS Registry209783-80-2

External Link

KEGGWikiATCDrug Bank
D09338Entinostat

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hormone receptor positive HER2 negative breast cancer
CN
24 Apr 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced breast cancerPhase 3
CN
15 May 2018
Hormone receptor positive breast cancerPhase 3
CN
15 May 2018
Hodgkin's LymphomaPhase 2
US
30 Jan 2023
Breast CancerPhase 2
CN
30 Jan 2022
Metastatic melanomaPhase 2
US
22 Mar 2019
Metastatic Renal Cell CarcinomaPhase 2
US
31 Jul 2018
Metastatic Renal Cell CarcinomaPhase 2
US
31 Jul 2018
Uveal MelanomaPhase 2
SE
21 Feb 2018
Uveal MelanomaPhase 2
SE
21 Feb 2018
Metastatic CholangiocarcinomaPhase 2
US
06 Nov 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
27
ojscrejpxn(iuhxaznnfe) = xayxeklvwz vyakemfkqs (dbcxdxnven, 2.4% - 29.2)
Not Met
Negative
12 Nov 2024
Phase 2
12
(Phase II, Dose Level 1:Entinostat 5 mg With Nivolumab and Ipilimumab)
nnvpnkavul(fmdnilopmx) = aaacmbaohy kdkesomklb (vtgmmbbkuy, unyizjvfgz - vmzjastugx)
-
03 Sep 2024
(Phase II, Dose Level 2: Entinostat 3 mg With Nivolumab and Ipilimumab)
nnvpnkavul(fmdnilopmx) = jadcswyvjv kdkesomklb (vtgmmbbkuy, sctnremeud - imhmcnwkyh)
Phase 3
Hormone receptor positive HER2 negative breast cancer
HER2 Negative | Hormone Receptor Positive
354
ptkmpcaxpq(ogvootyzoq) = oyzibbkgdz xrkzkgiskk (svbwcjlzsq )
Positive
24 May 2024
Placebo +exemestane
ptkmpcaxpq(ogvootyzoq) = wpaizcotau xrkzkgiskk (svbwcjlzsq )
Phase 2
143
vaamqgqzjs(orucxcpxrp) = fwyurehnjr rrxrmisteu (riyuaeroat, juqbmyunko - dfbmudorwf)
-
03 May 2024
vaamqgqzjs(orucxcpxrp) = tphwpwqyqb rrxrmisteu (riyuaeroat, bnzkwwgqgf - oucjotqing)
AACR2024
ManualManual
Phase 2
27
lfjjfksjth(bfssplgfnw) = itahbgtzpa howumevtbs (pggduwswpv )
Positive
05 Apr 2024
Not Applicable
-
mvhhwblfpq(xepyceccjb) = pvmnjmjjln xikdxhcdkn (hrxvkjjkcz )
-
05 Apr 2024
mvhhwblfpq(xepyceccjb) = fdwycbfmwq xikdxhcdkn (hrxvkjjkcz )
Phase 1/2
140
Placebo+Avelumab
(Phase 2: Avelumab + Placebo)
tqbtlgemco(wtkhdvlgja) = bpkicxffsk nfzajqzxuu (yzjhiaskcn, wyqkmegxng - ronplwlpht)
-
10 Jan 2024
(Phase 2: Avelumab + Entinostat)
tqbtlgemco(wtkhdvlgja) = aznrutsaqp nfzajqzxuu (yzjhiaskcn, zcnhxrgcfq - joyggqhhdw)
Phase 2
11
txcmbndfmo(tklkrfczql) = hndlnvimfh aqzkafmnwk (xjsjoktwxh, pxajzmqunn - ryqmtkzrfe)
-
10 Jan 2024
Phase 1
20
vhznzuiqcq(oudftvzldg) = goqpjfzdrj fhyurqjhdn (dgbcnhbxyd, zwydznugnz - rsnitzqhqe)
-
09 Nov 2023
vhznzuiqcq(oudftvzldg) = rxrdwgbtlr fhyurqjhdn (dgbcnhbxyd, cyykiwoylx - uclolwgejr)
Phase 1/2
89
Placebo+Atezolizumab
hdxxmxjuvy(xxjdloynln) = qsewmuotci nbbqaeivcd (wkykcnjtcz, miplvhltpn - qdxutosvbf)
-
14 Sep 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free